Published in Diabetologia on March 31, 2012
Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. N Engl J Med (2016) 4.52
PPARγ signaling and metabolism: the good, the bad and the future. Nat Med (2013) 3.71
Pioglitazone use and risk of bladder cancer: population based cohort study. BMJ (2016) 2.37
Thiazolidinediones and associated risk of bladder cancer: a systematic review and meta-analysis. Br J Clin Pharmacol (2014) 1.82
Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes. Cell Metab (2014) 1.53
Benign prostatic hyperplasia is a significant risk factor for bladder cancer in diabetic patients: a population-based cohort study using the National Health Insurance in Taiwan. BMC Cancer (2013) 1.51
Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis. CMAJ (2012) 1.50
Metformin use and lung cancer risk in patients with diabetes. Cancer Prev Res (Phila) (2015) 1.49
Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis. Diabetologia (2014) 1.46
Cancer risk for patients using thiazolidinediones for type 2 diabetes: a meta-analysis. Oncologist (2013) 1.41
PPARγ and the global map of adipogenesis and beyond. Trends Endocrinol Metab (2014) 1.26
Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease. World J Gastroenterol (2014) 1.20
Pharmacological agents for NASH. Nat Rev Gastroenterol Hepatol (2013) 1.15
Pioglitazone and risk of bladder cancer: clarification of the design of the French study. Diabetologia (2012) 1.15
Do we still need pioglitazone for the treatment of type 2 diabetes? A risk-benefit critique in 2013. Diabetes Care (2013) 1.12
Safety and tolerability of sitagliptin in type 2 diabetes: pooled analysis of 25 clinical studies. Diabetes Ther (2013) 1.11
Hospitalised hip fracture risk with rosiglitazone and pioglitazone use compared with other glucose-lowering drugs. Diabetologia (2012) 1.08
Pioglitazone for secondary prevention after ischemic stroke and transient ischemic attack: rationale and design of the Insulin Resistance Intervention after Stroke Trial. Am Heart J (2014) 1.08
Use of insulin and insulin analogs and risk of cancer - systematic review and meta-analysis of observational studies. Curr Drug Saf (2013) 1.05
Obesity and Diabetes: The Increased Risk of Cancer and Cancer-Related Mortality. Physiol Rev (2015) 1.03
Latest insights into the risk of cancer in diabetes. J Diabetes Investig (2013) 1.01
A Review on the Relationship between SGLT2 Inhibitors and Cancer. Int J Endocrinol (2014) 1.00
Comparing pioglitazone to insulin with respect to cancer, cardiovascular and bone fracture endpoints, using propensity score weights. Clin Drug Investig (2013) 0.98
Detection bias and overestimation of bladder cancer risk in type 2 diabetes: a matched cohort study. Diabetes Care (2013) 0.98
Diabetes mellitus increases the risk of bladder cancer: an updated meta-analysis of observational studies. Diabetes Technol Ther (2013) 0.98
Guideline approach to therapy in patients with newly diagnosed type 2 diabetes. Diabetes Care (2013) 0.95
Diabetes mellitus and risk of bladder cancer: a meta-analysis of cohort studies. PLoS One (2013) 0.93
β-cell dysfunction: Its critical role in prevention and management of type 2 diabetes. World J Diabetes (2015) 0.92
Use of the analytic hierarchy process for medication decision-making in type 2 diabetes. PLoS One (2015) 0.91
Diabetes mellitus and risk of bladder cancer: a meta-analysis of cohort studies. PLoS One (2013) 0.89
Efficacy and safety of lobeglitazone monotherapy in patients with type 2 diabetes mellitus over 24-weeks: a multicenter, randomized, double-blind, parallel-group, placebo controlled trial. PLoS One (2014) 0.89
The association of pioglitazone and urinary tract disease in type 2 diabetic Taiwanese: bladder cancer and chronic kidney disease. PLoS One (2014) 0.88
Pioglitazone, a PPARγ agonist, suppresses CYP19 transcription: evidence for involvement of 15-hydroxyprostaglandin dehydrogenase and BRCA1. Cancer Prev Res (Phila) (2012) 0.87
The peroxisome proliferator activated receptor-γ pioglitazone improves vascular function and decreases disease activity in patients with rheumatoid arthritis. J Am Heart Assoc (2013) 0.86
Treatment with insulin (analogues) and breast cancer risk in diabetics; a systematic review and meta-analysis of in vitro, animal and human evidence. Breast Cancer Res (2015) 0.85
Stay vigilant: a glitazone (pioglitazone) can hide a glitazar! Eur J Clin Pharmacol (2012) 0.84
Nonalcoholic fatty liver disease: new treatments. Curr Opin Gastroenterol (2015) 0.84
Effects of co-administration of candesartan with pioglitazone on inflammatory parameters in hypertensive patients with type 2 diabetes mellitus: a preliminary report. Cardiovasc Diabetol (2013) 0.83
Increased expression of SUMO1P3 predicts poor prognosis and promotes tumor growth and metastasis in bladder cancer. Oncotarget (2016) 0.83
Risk of bladder cancer among patients with diabetes treated with a 15 mg pioglitazone dose in Korea: a multi-center retrospective cohort study. J Korean Med Sci (2014) 0.83
Diabetes medications and cancer risk: review of the literature. Am Health Drug Benefits (2012) 0.81
Pioglitazone: A prudent prescription. Indian J Endocrinol Metab (2013) 0.81
Neuroprotective Properties of a Novel Non-Thiazoledinedione Partial PPAR- γ Agonist against MPTP. PPAR Res (2013) 0.80
The Influences of Withdrawal and Daily Dose Reduction of Pioglitazone on Metabolic Parameters in Patients With Type 2 Diabetes: A Retrospective Longitudinal Observational Study. J Clin Med Res (2016) 0.80
Risk of Malignant Neoplasms of Kidney and Bladder in a Cohort Study of the Diabetic Population in Taiwan With Age, Sex, and Geographic Area Stratifications. Medicine (Baltimore) (2015) 0.79
Drug treatment of type 2 diabetes mellitus in patients for whom metformin is contraindicated. Diabetes Metab Syndr Obes (2014) 0.79
Clinical neuroprotective drugs for treatment and prevention of stroke. Int J Mol Sci (2012) 0.79
Endothelium as a gatekeeper of fatty acid transport. Trends Endocrinol Metab (2013) 0.79
Impact of Medicine Withdrawal on Reporting of Adverse Events Involving Therapeutic Alternatives: A Study from the French Spontaneous Reporting Database. Drug Saf (2017) 0.78
Pioglitazone and risk of bladder cancer: clarification of the design of the French study. Reply to Perez AT [letter]. Diabetologia (2012) 0.78
Pioglitazone suspension and its aftermath: A wake up call for the Indian drug regulatory authorities. J Pharmacol Pharmacother (2013) 0.77
PPARγ in head and neck cancer prevention. Oral Oncol (2014) 0.77
Options for empagliflozin in combination therapy in type 2 diabetes mellitus. Int J Gen Med (2016) 0.76
Rosiglitazone reduces breast cancer risk in Taiwanese female patients with type 2 diabetes mellitus. Oncotarget (2016) 0.76
Importance of Beta Cell Function for the Treatment of Type 2 Diabetes. J Clin Med (2014) 0.76
Generalized enrichment analysis improves the detection of adverse drug events from the biomedical literature. BMC Bioinformatics (2016) 0.75
Letter: the risk of bladder cancer in korean diabetic subjects treated with pioglitazone (diabetes metab j 2012;36:371-8). Diabetes Metab J (2013) 0.75
Short-Term Risk of Bleeding During Heparin Bridging at Initiation of Vitamin K Antagonist Therapy in More Than 90 000 Patients With Nonvalvular Atrial Fibrillation Managed in Outpatient Care. J Am Heart Assoc (2016) 0.75
Conventional hypoglycaemic agents and the risk of lung cancer in patients with diabetes: a meta-analysis. PLoS One (2014) 0.75
Randomized placebo control study of insulin sensitizers (Metformin and Pioglitazone) in psoriasis patients with metabolic syndrome (Topical Treatment Cohort). BMC Dermatol (2016) 0.75
Update on Safety Issues Related to Antihyperglycemic Therapy. Diabetes Spectr (2014) 0.75
Pioglitazone utilization, efficacy & safety in Indian type 2 diabetic patients: A systematic review & comparison with European Medicines Agency Assessment Report. Indian J Med Res (2016) 0.75
Response: the risk of bladder cancer in korean diabetic subjects treated with pioglitazone (diabetes metab j 2012;36:371-8). Diabetes Metab J (2012) 0.75
Pathology of bladder cancer among diabetic patients undergoing radical cystectomy with a history of pioglitazone (Actos) use. BMC Urol (2014) 0.75
Pioglitazone and the Risk of Bladder Cancer: A Meta-Analysis. Diabetes Ther (2017) 0.75
The Low-Dose (7.5 mg/day) Pioglitazone Therapy. J Clin Med Res (2017) 0.75
Taurine and tea polyphenols combination ameliorate nonalcoholic steatohepatitis in rats. BMC Complement Altern Med (2017) 0.75
Metformin and reduced risk of cancer in diabetic patients. BMJ (2005) 13.04
The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia (2009) 10.95
Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care (2006) 7.99
Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care (2011) 5.63
Association between smoking and risk of bladder cancer among men and women. JAMA (2011) 4.31
Diabetes mellitus and risk of bladder cancer: a meta-analysis. Diabetologia (2006) 2.91
Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive. Drug Saf (2009) 2.67
French national health insurance information system and the permanent beneficiaries sample. Rev Epidemiol Sante Publique (2010) 2.08
Expression of peroxisome proliferator-activated receptors (PPARs) in human urinary bladder carcinoma and growth inhibition by its agonists. Int J Cancer (2003) 1.86
Cohort study of pioglitazone and cancer incidence in patients with diabetes. Diabetes Care (2011) 1.83
Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in human transitional bladder cancer and its role in inducing cell death. Neoplasia (1999) 1.78
Urothelial carcinogenesis in the urinary bladder of male rats treated with muraglitazar, a PPAR alpha/gamma agonist: Evidence for urolithiasis as the inciting event in the mode of action. Toxicol Pathol (2006) 1.49
Pharmacoepidemiological research using French reimbursement databases: yes we can! Pharmacoepidemiol Drug Saf (2010) 1.38
The effect of smoking on the male excess of bladder cancer: a meta-analysis and geographical analyses. Int J Cancer (2009) 1.29
Diabetes mellitus, hyperglycaemia and cancer. Diabetes Metab (2010) 1.23
[Reconstruction technic in the treatment of wide-neck intracranial aneurysms. Long-term angiographic and clinical results. Apropos of 56 cases]. J Neuroradiol (1997) 3.06
The "Remodelling Technique" in the Treatment of Wide Neck Intracranial Aneurysms. Angiographic Results and Clinical Follow-up in 56 Cases. Interv Neuroradiol (2001) 2.82
Long-term angiographic follow-up of 169 intracranial berry aneurysms occluded with detachable coils. Radiology (1999) 2.34
Delayed stroke secondary to increasing mass effect after endovascular treatment of a giant aneurysm by parent vessel occlusion. AJNR Am J Neuroradiol (2001) 2.23
French national health insurance information system and the permanent beneficiaries sample. Rev Epidemiol Sante Publique (2010) 2.08
Intracranial aneurysms: endovascular treatment with mechanical detachable spirals in 60 aneurysms. Radiology (1997) 1.83
Canadian experience with the pipeline embolization device for repair of unruptured intracranial aneurysms. AJNR Am J Neuroradiol (2012) 1.74
Sexual abuse is more frequently reported by IBS patients than by patients with organic digestive diseases or controls. Results of a multicentre inquiry. French Club of Digestive Motility. Eur J Gastroenterol Hepatol (1997) 1.72
Intracranial arterial aneurysms associated with arteriovenous malformations: endovascular treatment. Radiology (2001) 1.71
Patient-controlled interscalene analgesia after shoulder surgery: catheter insertion by the posterior approach. Anesth Analg (2005) 1.69
Intracranial berry aneurysms: angiographic and clinical results after endovascular treatment. Radiology (1998) 1.69
The retrograde approach: a consideration for the endovascular treatment of aneurysms. AJNR Am J Neuroradiol (2000) 1.58
Incidence, clinical and etiologic features, and outcomes of advanced chronic heart failure: the EPICAL Study. Epidémiologie de l'Insuffisance Cardiaque Avancée en Lorraine. J Am Coll Cardiol (1999) 1.57
Flow-related enhancement in the vertebral plexus mimicking an intramural hematoma. AJNR Am J Neuroradiol (1996) 1.52
Analysis by categorizing or dichotomizing continuous variables is inadvisable: an example from the natural history of unruptured aneurysms. AJNR Am J Neuroradiol (2011) 1.42
[Percutaneous vertebral surgery. Technics and indications]. J Neuroradiol (1997) 1.39
[Labour epidural analgesia in Martinique: evaluation of quality and accessibility to epidural analgesia by the patients in level one obstetric clinic]. Ann Fr Anesth Reanim (2004) 1.39
[Bio-banks: changes arising from the new bioethics law]. Rev Epidemiol Sante Publique (2006) 1.39
[Bariatric surgery in France: results of a nationwide prospective survey]. Ann Chir (2005) 1.38
Treatment of traumatic aneurysms and arteriovenous fistulas of the skull base by using endovascular stents. J Neurosurg (2001) 1.38
Hypersensitivity reactions to blood components: document issued by the allergy committee of the French medicines and healthcare products regulatory agency. J Investig Allergol Clin Immunol (2011) 1.34
[Descriptive study of digestive functional symptoms in the French general population]. Gastroenterol Clin Biol (1998) 1.12
Treatment of distal aneurysms of the cerebellar arteries by intraaneurysmal injection of glue. AJNR Am J Neuroradiol (1999) 1.11
Estimated risk of endocarditis in adults with predisposing cardiac conditions undergoing dental procedures with or without antibiotic prophylaxis. Clin Infect Dis (2006) 1.06
A randomized trial on the safety and efficacy of endovascular treatment of unruptured intracranial aneurysms is feasible. Interv Neuroradiol (2004) 1.04
Treatment of congestive heart failure: interfering the aldosterone-cardiac extracellular matrix relationship. Hypertension (2001) 1.03
Low exposure to sunlight is a risk factor for Crohn's disease. Aliment Pharmacol Ther (2011) 1.03
Prevalence and treatment of diabetes in France: trends between 2000 and 2005. Diabetes Metab (2008) 1.02
Myocardial collagen turnover in normotensive obese patients: relation to insulin resistance. Int J Obes (Lond) (2005) 0.99
Arteriovenous malformation of the mandible: embolization and direct injection therapy. J Vasc Interv Radiol (2001) 0.98
Effect of surgery under general anaesthesia on antipyrine clearance. Br J Clin Pharmacol (1978) 0.98
Endovascular treatment of distally located giant aneurysms. Neurosurgery (2000) 0.97
Local and regional adverse reactions to BCG-SSI vaccination: a 12-month cohort follow-up study. Vaccine (2009) 0.95
Acute pancreatitis following gastrointestinal endoscopy without ampullary cannulation. Endoscopy (1982) 0.95
[Carpal tunnel syndrome surgery in France in 2008: patients' characteristics and management]. Rev Neurol (Paris) (2011) 0.94
Percutaneous transluminal angioplasty and stenting of the proximal vertebral artery for symptomatic stenosis. AJNR Am J Neuroradiol (2000) 0.94
Basilar artery occlusion in a child: "clot angioplasty" followed by thrombolysis. Childs Nerv Syst (2000) 0.92
Seasonal influenza vaccination coverage in France during two influenza seasons (2007 and 2008) and during a context of pandemic influenza A(H1N1) in 2009. Vaccine (2011) 0.92
French medical practice in type 2 diabetes: the need for better control of cardiovascular risk factors. Diabetes Metab (2008) 0.89
[Influenza vaccination coverage in France in 2007-2008: contribution of vaccination refund data from the general health insurance scheme]. Med Mal Infect (2009) 0.89
[Screening for diabetes in France: data from the 2000-2001 cohort of the national medical insurance system]. Rev Epidemiol Sante Publique (2004) 0.89
Changes by age in breast cancer incidence, mammography screening and hormone therapy use in France from 2000 to 2006. Bull Cancer (2009) 0.88
Retinoic acid receptor and retinoid X receptor alterations in lung cancer precursor lesions. Cancer Res (2000) 0.88
Acrylic vertebroplasty in symptomatic cervical vertebral haemangiomas: report of 2 cases. Neuroradiology (1996) 0.88
Cancer prone persons. A randomized screening trial based on colonoscopy: background, design and recruitment. Fam Cancer (2001) 0.87
Enterococcal endocarditis in the beginning of the 21st century: analysis from the International Collaboration on Endocarditis-Prospective Cohort Study. Clin Microbiol Infect (2013) 0.86
[Measurement of functional inability and quality of life in cardiac failure. Transcultural adaptation and validation of the Goldman, Minnesota and Duke questionnaires]. Arch Mal Coeur Vaiss (1997) 0.86
Facial diplegia complicating a bilateral internal carotid artery dissection. Stroke (1999) 0.85
National estimate of multiple sclerosis incidence in France (2001-2007). Mult Scler (2012) 0.84
[Research in clinical epidemiology: which rules should be applied?]. Rev Epidemiol Sante Publique (2008) 0.83
Flow diversion in aneurysms trial: the design of the FIAT study. Interv Neuroradiol (2011) 0.83
The prevalence and cost of diabetes in metropolitan France: what trends between 1998 and 2000?*. Diabetes Metab (2003) 0.83
Prevalence of macrovascular complications and cardiovascular risk factors in people treated for diabetes and living in France: the ENTRED study 2001. Diabetes Metab (2008) 0.83
Etiologic factors of chronic bronchitis in dairy farmers. Case control study in the Doubs region of France. Chest (1993) 0.82
Assessment of diabetes screening by general practitioners in France: the EPIDIA Study. Diabet Med (2006) 0.82
[Profile and evolution of irritable bowel syndrome. Prospective national epidemiological study of 1301 patients followed-up for 9 months in Gastroenterology. Groupe d'Etude Nationale sur le Syndrome de l'Intestin Irritable (SII)]. Gastroenterol Clin Biol (1994) 0.82
Angiographic pitfall: duplicated tapered A1 segment of the anterior cerebral artery mimicking an anterior communicating artery aneurysm. Interv Neuroradiol (2011) 0.82
Unruptured intracranial aneurysms: their illusive natural history and why subgroup statistics cannot provide normative criteria for clinical decisions or selection criteria for a randomized trial. J Neuroradiol (2008) 0.82
Inhibition, activation, destruction, and induction of drug-metabolizing enzymes by trichloroethylene. Toxicol Appl Pharmacol (1979) 0.81
New Devices Designed to Improve the Long-Term Results of Endovascular Treatment of Intracranial Aneurysms. A Proposition for a Randomized Clinical Trial to Assess their Safety and Efficacy. Interv Neuroradiol (2004) 0.80
The excess mortality related to cardiovascular diseases and cancer among adults pharmacologically treated for diabetes--the 2001-2006 ENTRED cohort. Diabet Med (2014) 0.80
Pulmonary embolism from a parasitic cardiac clot secondary to hepatic alveolar echinococcosis. J Cardiovasc Surg (Torino) (1987) 0.80
Metabolic activation of trichloroethylene into a chemically reactive metabolite toxic to the liver. J Pharmacol Exp Ther (1978) 0.80
Some risk factors for cerebral palsy in very premature infants: importance of premature rupture of membranes and monochorionic twin placentation. Biol Neonate (1999) 0.80
[Tobacco, alcohol and psychotropic drugs in Lorraine, epidemiological survey of the general population]. Sante Publique (2005) 0.80
Inter- and intraobserver variability in the assessment of brain arteriovenous malformation angioarchitecture and endovascular treatment results. AJNR Am J Neuroradiol (2007) 0.79
Hepatitis B virus vaccination by French family physicians. Med Mal Infect (2011) 0.79
Quality of life and attitudes towards psychotropics and dependency: consumers vs. non-consumers aged 50 and over. J Clin Pharm Ther (2004) 0.79
Postdischarge adverse drug reactions in primary care originating from hospital care in France: a nationwide prospective study. Drug Saf (2001) 0.79
The role of CT in evaluation of the effectiveness of embolisation of spinal dural arteriovenous fistulae with N-butyl cyanoacrylate. Neuroradiology (1996) 0.79
Endovascular treatment of a cervical paraspinal arteriovenous malformation via arterial and venous approaches. AJNR Am J Neuroradiol (1999) 0.79
Pioglitazone and risk of bladder cancer: clarification of the design of the French study. Reply to Perez AT [letter]. Diabetologia (2012) 0.78
[The cost of diabetes in metropolitan France]. Diabetes Metab (2000) 0.78
Study to determine the efficacy of topical morphine on painful chronic skin ulcers. J Wound Care (2005) 0.78
[Risk factors for cardiac mortality in cases of syncope with previous history of myocardial infarction]. Arch Mal Coeur Vaiss (2003) 0.78
[Epidemiology of diabetes in metropolitan France]. Diabetes Metab (2000) 0.78
Cigarette smoking and the risk of colorectal adenoma in men. Scand J Gastroenterol (1991) 0.78
[Autoimmune hemolytic anemia during ulcerative rectocolitis. Cure by proctectomy]. Nouv Presse Med (1972) 0.78
Factors associated with the consumption of psychotropic drugs in a cohort of men and women aged 50 and over. J Clin Pharm Ther (2003) 0.78
Liquid embolization material reduces the delivered radiation dose: clinical myth or reality? AJNR Am J Neuroradiol (2011) 0.78